Rev Esp Quimioter 2017, 30(4):269-275

JUAN MARCO FIGUEIRA-GONÇALVES, NATALIA BETHENCOURT-MARTÍN, LINA INMACULADA PÉREZ-MÉNDEZ, DAVID DÍAZ-PÉREZ, CRISTINA GUZMÁN-SÁENZ, PEDRO VIÑA-MANRIQUE, ARTURO JOSÉ PEDRERO-GARCÍA

Introduction. One of the major microorganisms described as the cause of exacerbations of chronic obstructive pulmonary disease (COPD) is Streptococcus pneumoniae. The aim of this study is to evaluate the impact of 13-valent pneumococcal conjugate polysaccharide vaccine (PCV13) in COPD patients with regard to the development of exacerbations and the possible differential effect according to the patient’s phenotype.
Material and methods. Prospective observational study of patients with COPD and FEV1 ? 65% and 18-month follow-up. Main variables: vaccination status with PCV13, phenotype “exacerbator” or “non-exacerbator”, number of exacerbations, hospitalization and deaths. A descriptive statistical analysis was performed according to the nature of the variable and an inferential analysis with CI95%, bivariate contrasts, and multivariate analysis. Significance level 5%. The statistical packages EPIDAT 3.0 and SPSS version 21.0 were used.
Results. 121 patients were included. Twenty-four percent were labeled as phenotype exacerbator. 36% were vaccinated with PCV13. During follow-up, 68% of patients had at least one exacerbation and 27% required hospitalization. We observed similarity (p> 0.05) in the number of exacerbations and deaths; however, the percentage of hospitalization in the vaccinated was 18%, compared to 32% in the non-vaccinated group. In the multivariate adjustment (controlling for the phenotype), an adjusted OR of 2.77 risk of hospitalization was observed in the non-vaccinated group (p = 0.044).
Conclusions. Non-vaccination with PCV13 almost triples the risk of hospitalization in patients with COPD.

Rev Esp Quimioter 2017; 30(4):269-275 [pdf]